The federal False Claims Act FCA remained in flux in 2022, marked by significant activity at the appellate level. DOJ’s enforcement of the FCA remained robust, headlined by a $900 million settlement with Biogen, Inc. arising out of an Anti-Kickback Statute violation.
We previously reported that the Fourth Circuit, via a 2-1 decision in United States ex rel. Sheldon v. Allergan Sales, LLC, 24 F.4th 340 (4th Cir. 2022), affirmed the dismissal of a.
A Fourth Circuit ruling in a False Claims Act case has created a 4-4 circuit split over the issue of the act’s knowledge requirement, Bradley partner Elisha Kobre explains. This makes.
Litigation involving drug price reporting under the Medicaid Drug Rebate Program (MDRP) has been very active in 2022. Most recently, on August 3, 2022, an Illinois federal jury.